




Searching News Database: EvaMist
HSMN NewsFeed - 29 Sep 2014
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
HSMN NewsFeed - 30 Jul 2007
KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist(TM)
KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist(TM)
HSMN NewsFeed - 21 Jun 2007
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
HSMN NewsFeed - 18 May 2007
KV Pharmaceutical Company Announces Approval for Two Strengths of Generic Versions of Toprol-XL(R)
KV Pharmaceutical Company Announces Approval for Two Strengths of Generic Versions of Toprol-XL(R)
HSMN NewsFeed - 16 May 2007
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
HSMN NewsFeed - 1 Nov 2006
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
HSMN NewsFeed - 10 May 2006
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
Additional items found! 11

Members Archive contains
11 additional stories matching:
EvaMist
(Password required)
EvaMist
(Password required)